Briefing
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
Recruiting phase 2 trial using circulating tumor DNA to risk-adapt postoperative therapy for HPV-associated oropharyngeal cancer (planned n=50).
- Design: Phase 2 · Recruiting